drugset / Trial / NCT03266913

Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia

NCT03266913

Phase 3 Unknown 126 enrolled Hormozgan University of Medical Sciences
RandomizedParallel-groupSingle-blindTreatment

Summary

Neonatal Jaundice occurs in 60% of term infants and 80% of premature infants. Although it is transient, it is associated with high rate of readmission of patients in the first week of infancy. Neonatal jaundice can cause neurological complications and kernicterus. Considering the fact that there have been a lot of studies on probiotic role in management of necrotizing enterocolitis (NEC) and few studies on their role in neonatal jaundice, we carried out this study to determine the efficacy and safety of probiotics in neonatal hyperbilirubinemia in infants hospitalized in children hospital in Bandar Abbas.

Timeline

Start
2017-08-01
Primary completion
2017-10-01
Completion
2017-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator VSL#3 Other / unclassified 10 unknown Oral

Indications